Strata Critical Medical, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Earnings per Common Share (Tables)

Earnings per Common Share (Tables)

6 Months Ended

Jun. 30, 2026

Summary of Reconciliation of Net Income (Loss) and Common Stock Share Amounts

A reconciliation of net income (loss) and common share amounts used in the computation of basic and diluted income (loss) per common share is presented below.


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025











Numerator:
Net loss from continuing operations	$	(10,516)	$	(3,409)	$	(8,114)	$	(5,021)
Net loss from discontinued operations	—		(334)		(248)		(2,215)
Net loss	$	(10,516)	$	(3,743)	$	(8,362)	$	(7,236)









Denominator:
Total weighted-average common shares outstanding	86,213,930		81,297,402		85,770,897		80,598,483






Basic and diluted earnings (loss) per share
Continuing operations	$	(0.12)	$	(0.04)	$	(0.10)	$	(0.06)
Discontinued operations	—		(0.01)		—		(0.03)
Total basic and diluted earnings (loss) per share	$	(0.12)	$	(0.05)	$	(0.10)	$	(0.09)

Summary of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following table represents common stock equivalents that were excluded from the computation of diluted loss per share for the three and six months ended June 30, 2026 and 2025 because the effect of their inclusion would be anti-dilutive as the Company was in a net loss position.


	Three Months Ended June 30,		Six Months Ended June 30,
	2026	2025	2026	2025


Warrants to purchase shares of common stock (1)	—	14,166,644	—	14,166,644
Options to purchase shares of common stock	2,584,248	3,509,029	2,584,248	3,509,029
Outstanding shares in escrow (2)	1,041,969	—	1,041,969	—
Restricted shares of common stock	12,258,111	10,818,888	12,258,111	10,818,888
Total potentially dilutive securities	15,884,328	28,494,561	15,884,328	28,494,561

(1) The warrants expired in accordance with their original terms on May 7, 2026. For the three and six months ended June 30, 2025, warrants are excluded because the effect of their inclusion would be anti-dilutive as their exercise price exceeds the average market price of the Company’s common stock.

(2) 1,041,969 shares remaining in escrow to cover potential indemnification obligations for breaches of general representations and warranties under the Keystone Purchase Agreement. These shares are legally issued and outstanding but are excluded from the weighted average shares outstanding calculation as they are contingently returnable pending expiration of the representations and warranties survival period in September 2026.